Ross Galin


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

Ross Galin Co-Chairs O’Melveny’s Life Sciences Industry Group and the firm’s State Attorneys General Practice. Ross represents corporations and individual clients in civil, regulatory, and criminal matters. His practice includes representing companies, executives and employees in government enforcement actions, civil qui tam litigation, and providing compliance advice. His clients include pharmaceutical and medical device companies and their executives and employees. Ross handles government enforcement actions and False Claims Act litigation, and provides life sciences law compliance advice.

Ross regularly conducts internal investigations, both of alleged misconduct and to proactively assess risk, on behalf of major life sciences companies and corporations across all industries. He has conducted 100+ internal compliance investigations for pharmaceutical companies alone. Ross is recognized in the 2018 edition of The Legal 500 as among the leading attorneys in the US for Health Care: Life Sciences.

Ross also represents corporate clients in a variety of securities and general commercial litigation matters in federal and state courts. Ross formerly led the firm’s associate and counsel work coordination system, supporting the efficient staffing of client matters and opportunity for attorney development.

Honors & Awards

  • The Legal 500 US in Healthcare - Life Sciences (2017-2022)
  • Super Lawyers “Rising Star” in General Litigation (2011)


Bar Admissions

  • New York

Court Admissions

  • US District Court, Eastern and Southern Districts of New York


  • Fordham University, J.D.: cum laude; Order of the Coif; Managing Editor, Fordham Law Review 
  • University of Michigan, B.A., Political Science, B.A., History; Class Honors for Academic Achievement

Professional Activities


  • Honorable John F. Keenan, US District Court, Southern District of New York


  • Trial lawyer in what The New York Times called “one of the most complicated and gargantuan legal battles in American history,” defending an industry-leading pharmaceutical and consumer products company at trial in the nation’s first opioid case to go to trial.
  • Defending an industry-leading pharmaceutical and consumer products company in nationwide litigation over prescription opioid medications, including multi-district litigation and State AG litigations across the country.
  • Representing a life sciences company in a New York State Department of Financial Services investigation regarding the promotion of its products.
  • Secured a DOJ declination and a dismissal of a False Claims Act lawsuit brought against a major pharmaceutical company regarding its patient support services.
  • Representing a leading international pharmaceutical company in an investigation by the US Department of Justice into the company’s charitable giving.
  • Representing a leading global property management company in a matter opposite the Port Authority of NY/NJ and the New York AG’s Office.
  • Representing a real estate firm in a New Jersey Task Force investigation regarding tax incentives.
  • Represented a leading pharmaceutical and consumer goods company, and its subsidiaries, in an investigation brought by 48 state attorneys general related to its metal-on-metal hip replacement systems, and separately helped its subsidiary negotiate a favorable settlement with the Oregon attorney general, which instituted its own investigation.
  • Represented a leading pharmaceutical and consumer goods company, and its subsidiary medical device manufacturer, in a 43-state Attorney General investigation of consumer protection/deceptive trade practice concerns regarding pelvic mesh products.
  • Secured a complete declination from the government on relator's claims against our client, a leading pharmacy benefits manager, after a two-year federal False Claims Act investigation by the  US Attorney's Office for the Southern District of New York, the Department of Justice, and the District of Rhode Island. 
  • Successfully persuaded the Department of Health and Human Services Office of Inspector General to reverse course in separate exclusion actions against Howard Solomon, Chairman of Forest Laboratories, and the CEO of another leading life sciences company.
  • Persuaded the SEC to close its investigation of CTI BioPharma regarding its public disclosures and alleged violations of the antifraud and certain other provisions of the federal securities laws without pursuing an enforcement action.
  • Represented multiple major pharmaceutical companies in Department of Justice investigations of off-label promotion and kickback allegations.
  • Has represented life sciences companies, officers, and directors in securities class actions, and derivative lawsuits.
  • Represents companies in consumer protection act cases. Representations have included cases brought by private plaintiffs as well as those brought by state attorneys general’s offices. 
  • Obtained dismissal of a securities class action complaint against a former officer of a pharmaceuticals company alleging misrepresentations regarding the safety profile of the company’s pain medications.